Document is current
Any future updates will be listed below
-
Authors
Cheng, Yue
Tang, Honghu
Qing, Yufeng
Liu, Yuan
Yang, Lei
Dang, Wantai
Yu, Jing
Li, Rongbin
Liu, Huaxiang
Jiang, Zhenyu
Sun, Hongsheng
Yin, Songlou
Cheng, Jianzhao
Li, Zhijun
Fan, Wenqiang
Zhang, Hong
Du, Hongwei
Fu, Zili
Ma, Xinmei
Wu, Jian
Duan, Lihua
Zhang, Rong
Lin, Jinying
Da, Zhanyun
Wei, Wei
Zhai, Qianxun
Wu, Bingjie
Yi, Xiaowei
Jin, Xiaoping
Ge, Junyou
Feng, Ping
Liu, Yi
-
Funding
Funding for this research was provided by:
This trial received funding from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd..
- License Information
-
More Information
Article History
Received: 7 August 2025
Accepted: 1 December 2025
First Online: 9 December 2025
Declarations
:
: This multicenter trial involving 29 research centers in China was approved by local institutional review boards, including the Independent Ethics Committee of West China Hospital [2020 Clinical Trial (Western Medicine) Approval No. 191]. All patients provided written, informed consent prior to participation.
: Not applicable.
: Bingjie Wu, Xiaowei Yi, Xiaoping Jin, Junyou Ge are employees of the Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. The other authors declare no potential conflicts of interest.
